Literature DB >> 2862897

Effects of locally and systemically administered cholinoceptor antagonists on the secretory response of human eccrine sweat glands to carbachol.

J Longmore, C M Bradshaw, E Szabadi.   

Abstract

Eleven healthy male volunteers participated in a study comparing the effects of locally and systemically administered cholinoceptor antagonists on the secretory response of sweat glands to intradermally injected carbachol chloride. Atropine sulphate administered locally into the skin antagonised the response to carbachol: the dose-response curve for carbachol was shifted to the right without any depression of the maximum of the curve. The nicotinic receptor antagonists hexamethonium bromide and (+)-tubocurarine chloride, however, had little effect on the response to carbachol. Atropine sulphate, administered systemically by intramuscular injection, caused a non-surmountable antagonism of the response to carbachol: the maximum of the dose-response curve was depressed with little change in the value of ED50. Atropine methonitrate (a mixed muscarinic/nicotinic receptor antagonist), and hexamethonium bromide (a nicotinic receptor antagonist), both with poor access to the central nervous system, were injected intramuscularly: both caused non-surmountable antagonism of the response to carbachol. It is concluded that the response to carbachol is mediated by muscarinic rather than nicotinic receptors. The effect of atropine sulphate on the response to carbachol depends on the route of administration: while locally applied atropine sulphate appears to act as a competitive antagonist, systemically applied atropine sulphate, like atropine methonitrate and hexamethonium bromide, appears to act in a non-competitive manner. It is suggested that the systemically administered cholinoceptor antagonists reduce the response to carbachol by interacting with cholinoceptors in sympathetic ganglia: such an interaction would reduce the impulse flow in sudomotor fibres resulting in decreased sensitivity of the sweat glands to carbachol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862897      PMCID: PMC1400624          DOI: 10.1111/j.1365-2125.1985.tb02791.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Statistical estimations in enzyme kinetics.

Authors:  G N WILKINSON
Journal:  Biochem J       Date:  1961-08       Impact factor: 3.857

2.  The pharmacology of tropane compounds in relation to their steric structure.

Authors:  L GYERMEK; K NADOR
Journal:  J Pharm Pharmacol       Date:  1957-04       Impact factor: 3.765

3.  The pharmacology of sweating.

Authors:  W C RANDALL; K K KIMURA
Journal:  Pharmacol Rev       Date:  1955-09       Impact factor: 25.468

Review 4.  Antiacetylcholine drugs: chemistry, stereochemistry, and pharmacology.

Authors:  T D Inch; R W Brimblecombe
Journal:  Int Rev Neurobiol       Date:  1974       Impact factor: 3.230

Review 5.  The stimulation of eccrine sweating by pharmacologic agents.

Authors:  R L Dobson; K Sato
Journal:  Adv Biol Skin       Date:  1972

6.  A technique for studying the effects of drugs on human sweat gland activity.

Authors:  M Clubley; C E Bye; T Henson; A W Peck; C Riddington
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

7.  The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitriptyline and desipramine in human volunteers.

Authors:  E Szabadi; P Gaszner; C M Bradshaw
Journal:  Br J Psychiatry       Date:  1980-11       Impact factor: 9.319

8.  Pharmacological responsiveness of sweat glands in anxious patients and healthy volunteers.

Authors:  S Maple; C M Bradshaw; E Szabadi
Journal:  Br J Psychiatry       Date:  1982-08       Impact factor: 9.319

9.  The effects of a psychological "stressor" and raised ambient temperature on the pharmacological responsiveness of human eccrine sweat glands: implications for sweat gland hyper-responsiveness in anxiety states.

Authors:  M D van den Broek; C M Bradshaw; E Szabadi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  The responsiveness of human eccrine sweat glands to choline and carbachol. Application to the study of peripheral cholinergic functioning in Alzheimer-type dementia.

Authors:  K Lamb; C M Bradshaw; E Szabadi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  7 in total

1.  A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers.

Authors:  S R Flett; E Szabadi; C M Bradshaw
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  The effect of diazepam on the responsiveness of human eccrine sweat glands to carbachol: influence of ambient temperature.

Authors:  W Banjar; J Longmore; C M Bradshaw; E Szabadi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers.

Authors:  N Brion; D Beaumont; C Advenier
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

4.  A comparison of the effects of single doses of amoxapine and amitriptyline on autonomic functions in healthy volunteers.

Authors:  M Bourne; E Szabadi; C M Bradshaw
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.

Authors:  William P Cheshire; Robert D Fealey
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 6.  [The extraneuronal cholinergic system of the skin. Basic facts and clinical relevance].

Authors:  H Kurzen
Journal:  Hautarzt       Date:  2004-05       Impact factor: 0.751

7.  Effects of locally administered anticholinesterase agents on the secretory response of human eccrine sweat glands to acetylcholine and carbachol.

Authors:  J Longmore; B Jani; C M Bradshaw; E Szabadi
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.